4555.TSE · Sawai Pharmaceutical Co., Ltd

-

Please sign in to comment on 4555.TSE

1 Comment

Admin

4 years, 1 month ago

Sawai Group Holdings Co., Ltd is currently in a long term uptrend where the price is trading 4.7% above its 200 day moving average.

From a valuation standpoint, the stock is 98.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.

Sawai Group Holdings Co., Ltd's total revenue rose by 5.5% to $53B since the same quarter in the previous year.

Its net income has increased by 3.8% to $7B since the same quarter in the previous year.

Finally, its free cash flow fell by 44.8% to $-1B since the same quarter in the previous year.

Based on the above factors, Sawai Group Holdings Co., Ltd gets an overall score of 4/5.

Exchange	TSE
CurrencyCode	JPY
ISIN	JP3323050009
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

Beta	0.38
PE Ratio	12.16
Target Price	6488
Market Cap	235B
Dividend Yield	2.4%

ABOUT

Sawai Pharmaceutical Co., Ltd

Sawai Pharmaceutical Co., Ltd. manufactures, sells, imports, and exports pharmaceutical products in Japan and the United States. The company offers drugs in various formulations, including tablets, oral dispersing tablets, capsules, granules, injections, tapes, ophthalmic/nasal solutions, syrups, etc. in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, chemotherapeutics, vitamins, anti-cancer, etc. It serves hospitals, general practitioners, and dispensing pharmacies. Sawai Pharmaceutical Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.

4555.TSE · Sawai Pharmaceutical Co., Ltd

-

Sawai Pharmaceutical Co., Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Sawai Pharmaceutical Co., Ltd using a moving average strategy